Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

B2 Adrenergic Receptor Gene Polymorphism in Bronchial Asthma (polymorphism)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03118869
Recruitment Status : Unknown
Verified August 2017 by Aliae AR Mohamed Hussein, Assiut University.
Recruitment status was:  Active, not recruiting
First Posted : April 18, 2017
Last Update Posted : August 28, 2017
Sponsor:
Information provided by (Responsible Party):
Aliae AR Mohamed Hussein, Assiut University

Tracking Information
First Submitted Date April 11, 2017
First Posted Date April 18, 2017
Last Update Posted Date August 28, 2017
Actual Study Start Date April 1, 2017
Estimated Primary Completion Date October 1, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: April 13, 2017)
To measure number of patient with homozygous and heterozygous B2AD gene polymorphisms with focus on Arg/Gly16 and Gln/Glu27 polymorphism [ Time Frame: 1 month ]
study of prevalence homozygote and heterozygote patients
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: April 13, 2017)
Number of patient with b2AR gene polymorphisms in different asthma severity and different response of treatment of asthma ( Arg/Gly16 and Gln/Glu27 polymorphism) [ Time Frame: 1 month ]
correlation between polymorphism and pulmonary function test and level of disease control
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title B2 Adrenergic Receptor Gene Polymorphism in Bronchial Asthma
Official Title B2adrenergic Receptor Gene Polymorphism in Bronchial Asthma: Relation to Disease Severity and Control
Brief Summary

The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection. The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection, Enhanced mucociliary clearance.

The b2AR gene is located on chromosome 5q31-q32, a region that is genetically linked to asthma and related phenotypes. There are three best known polymorphisms in the coding region of the b2AR gene that can modulate the function of the receptor.

Detailed Description

Asthma is a complex disease and has a strong genetic component in its pathogenesis. So far, considerable efforts have been made to evaluate the association between genetic variants and asthma risk, and numerous genes have been identified as asthma Reporting Items susceptible genes.

The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection. The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection, Enhanced mucociliary clearance.

The b2AR gene is located on chromosome 5q31-q32, a region that is genetically linked to asthma and related phenotypes. There are three best known polymorphisms in the coding region of the b2AR gene that can modulate the function of the receptor.

Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Patients diagnosed as asthma according to GINA 2016
Condition
  • Gene Abnormality
  • Asthma
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Mohamed-Hussein AAR, Sayed SS, Eldien HMS, Assar AM, Yehia FE. Beta 2 Adrenergic Receptor Genetic Polymorphisms in Bronchial Asthma: Relationship to Disease Risk, Severity, and Treatment Response. Lung. 2018 Dec;196(6):673-680. doi: 10.1007/s00408-018-0153-3. Epub 2018 Sep 3.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: April 13, 2017)
75
Original Estimated Enrollment Same as current
Estimated Study Completion Date October 30, 2017
Estimated Primary Completion Date October 1, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • patients diagnosed as asthma according to GINA guideline 2016.
  • Allergic asthma

Exclusion Criteria:

  • pneumonia
  • chronic cardiac, hepatic and renal diseases
  • pregnancy and lactation
  • malignancy
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Egypt
Removed Location Countries  
 
Administrative Information
NCT Number NCT03118869
Other Study ID Numbers AssiutU3
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party Aliae AR Mohamed Hussein, Assiut University
Study Sponsor Assiut University
Collaborators Not Provided
Investigators
Principal Investigator: Aliae Mohamed-Hussein Professor of Pulmonology- Faculty of Medicine-Assiut University
PRS Account Assiut University
Verification Date August 2017